DrugPatentWatch Database Preview
AVASTIN Drug Profile
Summary for Tradename: AVASTIN
| Patents: | 858 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for AVASTIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AVASTIN |
Recent Clinical Trials for AVASTIN
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Fourth Military Medical University | Phase 2/Phase 3 |
| University of Texas Southwestern Medical Center | Phase 2 |
| National Comprehensive Cancer Network | Phase 2 |
Recent Litigation for AVASTIN
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
| Genentech, Inc. v. Pfizer Inc. | 2019-04-05 |
| Genentech, Inc. v. Immunex Rhode Island Corp. | 2019-03-29 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Forty Seven, Inc. | 2018-01-08 |
| Pfizer Inc. | 2018-01-05 |
| Hospira, Inc. | 2016-09-09 |
Pharmacology for AVASTIN
Company Disclosures: US Patents for AVASTIN
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | Orphan | company |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Biogen, Inc. (Cambridge, MA) | 2020-08-05 | RX | Orphan | company |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for AVASTIN
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) | 2035-03-27 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) | 2035-12-11 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for AVASTIN
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010286642 | Start Trial |
| China | 106659716 | Start Trial |
| European Patent Office | 2391419 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AVASTIN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 92780 | Luxembourg | Start Trial | PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826 |
| 93138 | Luxembourg | Start Trial | PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326 |
| CA 2015 00043 | Denmark | Start Trial | PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
